Results 21 to 30 of about 187,458 (237)

Btk regulates macrophage polarization in response to lipopolysaccharide [PDF]

, 2014
Bacterial Lipopolysaccharide (LPS) is a strong inducer of inflammation and does so by inducing polarization of macrophages to the classic inflammatory M1 population.
A Arranz, A Mansell, A Mantovani, A Mantovani, A Sica, Adrien Kissenpfennig, AJ Fleetwood, AL Amoras, AL Pauleau, BT Costa-Carvalho, C Porta, Caroline A. Jefferies, Claire Wynne, D Hata, DK Mohammad, E Hams, EE Ghosn, Emily Hams, F Antignano, F Porcheray, F Uckun, F Xu, FO Martinez, H An, H Jyonouchi, H Taneichi, H Yu, J Kitaura, J Orme, James A. Johnston, Jennifer C. Byrne, JI Odegaard, JN Gabhann, Joan Ní Gabhann, Kevin Currie, KG Lee, Kiva Brennan, KJ Livak, LA Honigberg, LM Sly, M Kortylewski, M Takahashi-Tezuka, MC Gagliardi, MJ Rauh, MS Shabestari, NB Hao, NE Mangan, NJ Horwood, NJ Horwood, OJ D’Cruz, P Dasgupta, P Pelegrin, P Sinha, P Smith, Padraic G. Fallon, Q Li, R Perez de Diego, R Shechter, RA Taha, RM O’Connell, RW Hendriks, S Akira, S Gordon, S Ostrand-Rosenberg, S Spence, SB Weisser, Shaun Spence, Siobhán Smith, SL Doyle, SL Doyle, SL Lin, T Krausgruber, TA Reese, TR Ramalingam, X Hu, X Li, X Liao, X Liu, Y Kawakami, Y Ohmori   +79 more
core   +8 more sources

Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Clinical Cancer Research, 2020
Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse is poor, and treatment choices are limited.
Yuqin Song, K. Zhou, D. Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, J. Ji, Wei Xu, Jie Jin, F. Lv, R. Feng, Sujun Gao, Haiyi Guo, Lei Zhou, R. Elstrom, Jane E. Huang, W. Novotny, R. Wei, Jun Zhu   +19 more
semanticscholar   +1 more source

Bruton's Tyrosine Kinase Inhibitors: Recent Updates. [PDF]

Int J Mol Sci
Bruton’s tyrosine kinase (BTK) inhibitors have revolutionized the landscape for the treatment of hematological malignancies, solid tumors, and, recently, autoimmune disorders.
Fares A, Carracedo Uribe C, Martinez D, Rehman T, Silva Rondon C, Sandoval-Sus J.   +5 more
europepmc   +2 more sources

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis & Rheumatology, 2021
Fenebrutinib (GDC‐0853) is a noncovalent, oral, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK). The efficacy, safety, and pharmacodynamics of fenebrutinib in systemic lupus erythematosus (SLE) were assessed in this phase II, multicenter,
D. Isenberg, R. Furie, N. S. Jones, P. Guibord, J. Galanter, Chin H Lee, A. Mcgregor, Balazs Toth, J. Rae, O. Hwang, Rupal H Desai, A. Lokku, N. Ramamoorthi, J. Hackney, P. Miranda, Viviane A de Souza, J. Jaller-Raad, A. Maura Fernandes, Rodrigo García Salinas, L. Chinn, M. Townsend, A. Morimoto, K. Tuckwell   +22 more
semanticscholar   +1 more source

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M, Lawes, Matthew J, MacEwan, David J, Murray, Megan Y, Rushworth, Stuart A, Shafat, Manar S., Zaitseva, Lyubov   +6 more
core   +2 more sources

Regulatory phosphorylation of Ikaros by Bruton's tyrosine kinase. [PDF]

PLoS ONE, 2013
Diminished Ikaros function has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Therefore, a stringent regulation of Ikaros is of paramount importance for normal lymphocyte ontogeny ...
Hong Ma, Sanjive Qazi, Zahide Ozer, Jian Zhang, Rita Ishkhanian, Fatih M Uckun   +5 more
doaj   +1 more source

Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials

Journal of Xenobiotics, 2023
Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti-D antibodies are the commonly used initial treatments for ITP.
Muhammad Ashar Ali, Muhammad Yasir Anwar, Wajeeha Aiman, Gurneel Dhanesar, Zainab Omar, Mohammad Hamza, Maha Zafar, Harish Kumar Rengarajan, Michael Maroules   +8 more
doaj   +1 more source

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani, Alam, Ashino, Baba, Bendall, Billottet, Burger, Burger, Byrd, Chang, Cordle, Dasmahapatra, David J. MacEwan, de Weers, Dos Santos, Doyle, Fiedler, Gallay, Grandage, Gu, Guzman, Hahn, Herman, Herrmann, Honda, Honigberg, Horwood, Ishii, Juliusson, Kawakami, Kim, Kojima, Kristian M. Bowles, Kvinlaug, Lyubov Zaitseva, Megan Y. Murray, Min, Mohamed, Nanri, Park, Quek, Renneville, Rushworth, Rushworth, Rushworth, Shinners, Sivina, Spiekermann, Stuart A. Rushworth, Sujobert, Tai, Tamburini, Tomasson, Tsukada, Vellenga, Venkataraman, Vetrie, Welch, Westermann, Zaitseva   +59 more
core   +1 more source

Disseminated fungal infection in a patient receiving zanubrutinib

Clinical Case Reports, 2023
Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh, Alice Xu, Zuhair Ballas, Rolando Sanchez   +3 more
doaj   +1 more source

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G, Changou, C, Chintapalli, S, Evans, CP, Guo, W, Kumaresan, P, Kung, H-J, Lam, KS, Liu, R, Ma, A-H, Mazloom, A, Patterson, R, Sanchez, E, Xiao, K, Xiao, W, Yang, JC, Yeh, C-T   +16 more
core   +2 more sources